BI Asset Management Fondsmaeglerselskab A S Invests $7.03 Million in Encompass Health Corporation $EHC

BI Asset Management Fondsmaeglerselskab A S bought a new position in Encompass Health Corporation (NYSE:EHC) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 72,675 shares of the company’s stock, valued at approximately $7,030,000.

A number of other institutional investors have also recently bought and sold shares of EHC. WPG Advisers LLC increased its position in Encompass Health by 73.3% during the fourth quarter. WPG Advisers LLC now owns 324 shares of the company’s stock worth $34,000 after purchasing an additional 137 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Encompass Health during the fourth quarter worth about $37,000. Assetmark Inc. increased its stake in Encompass Health by 88.1% during the third quarter. Assetmark Inc. now owns 299 shares of the company’s stock worth $38,000 after acquiring an additional 140 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Encompass Health by 36,200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock worth $46,000 after purchasing an additional 362 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new position in shares of Encompass Health in the 4th quarter worth about $55,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the transaction, the executive vice president directly owned 24,755 shares in the company, valued at approximately $2,588,382.80. This represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.80% of the company’s stock.

Encompass Health Price Performance

EHC stock opened at $97.94 on Monday. The firm has a market cap of $9.72 billion, a P/E ratio of 16.35, a price-to-earnings-growth ratio of 2.14 and a beta of 0.72. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99. The stock has a 50-day simple moving average of $103.92 and a 200-day simple moving average of $103.98.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Thursday, April 30th. The company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.51 by $0.09. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.Encompass Health’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.37 EPS. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, equities analysts predict that Encompass Health Corporation will post 5.97 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s payout ratio is presently 12.69%.

Analyst Ratings Changes

EHC has been the subject of a number of research reports. TD Cowen began coverage on Encompass Health in a report on Thursday, May 28th. They set a “buy” rating and a $125.00 target price for the company. Leerink Partners set a $152.00 price target on shares of Encompass Health in a report on Friday, May 22nd. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Barclays decreased their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Encompass Health in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $143.86.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.